Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510)
- PMID: 37549879
- DOI: 10.1016/j.jogoh.2023.102640
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510)
Keywords: Follitropin alfa; Real world study; Recombinant human follicle-stimulating hormone alfa.
Conflict of interest statement
Declaration of Competing Interest Juan-Enrique Schwarze, Claire Castello-Bridoux, Christoph Helwig, Thomas D'Hooghe, Susana Montenegro, Monica Lispi are employees of Merck Healthcare KGaA, Darmstadt, Germany or affiliate. Sebastien Marque is a full-time employee of Horiana company, Bordeaux, France.
Comment in
-
Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640).J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102644. doi: 10.1016/j.jogoh.2023.102644. Epub 2023 Aug 11. J Gynecol Obstet Hum Reprod. 2023. PMID: 37573940 No abstract available.
Comment on
-
A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.J Gynecol Obstet Hum Reprod. 2023 Jan;52(1):102510. doi: 10.1016/j.jogoh.2022.102510. Epub 2022 Nov 17. J Gynecol Obstet Hum Reprod. 2023. PMID: 36403900
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
